---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-021605"
form_type: "8-K"
ticker: "BBLG"
cik: "0001419554"
company_name: "Bone Biologics Corp"
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T22:29:00.236824+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bone Biologics prices $5M underwritten public offering of 2.5M shares at $1.97/share

## Summary
- Gross proceeds of approximately $5.0 million from sale of 2,538,071 shares of common stock at $1.97 per share.
- Underwriters granted 45-day over-allotment option to purchase up to 253,807 additional shares.
- Offering expected to close on or about June 16, 2023, subject to customary conditions.
- EF Hutton, division of Benchmark Investments, acting as sole book-running manager.
- Registration statement on Form S-1 (No. 333-271558) declared effective by SEC on June 14, 2023.

## SEC filing metadata
- accession: 0001493152-23-021605
- form_type: 8-K
- ticker: BBLG
- cik: 0001419554
- company_name: Bone Biologics Corp
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419554/000149315223021605/0001493152-23-021605-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419554/000149315223021605/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-021605
- JSON: https://secwatch.observer/filing/0001493152-23-021605.json
- Plain text: https://secwatch.observer/filing/0001493152-23-021605.txt

## Key facts
- Material Agreements
  Bone Biologics Corp entered into Underwriting Agreement with EF Hutton, division of Benchmark Investments, LLC valued at 2,538,071 shares of common stock at $1.97 per share; underwriter option for up to 380,710 additional (effective 2023-06-14).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: EF Hutton, division of Benchmark Investments, LLC
  - Value: 2,538,071 shares of common stock at $1.97 per share; underwriter option for up to 380,710 additional
  - Effective: 2023-06-14
  source text: On June 14, 2023, Bone Biologics Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with EF Hutton, division of Benchmark Investments, LLC (“EF Hutton”) acting as representatives of the several underwriters (the “Underwriters”) in connection with a public offering (the “Offering”) of the Company’s securities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419554/000149315223021605/0001493152-23-021605-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.